{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:26:31Z","timestamp":1790011591089,"version":"4.0.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/ftd.0b013e3181858ca9","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T07:10:01Z","timestamp":1223449801000},"page":"628-633","source":"Crossref","is-referenced-by-count":53,"title":["ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety"],"prefix":"10.1097","volume":"30","author":[{"given":"Arzu","family":"Gunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF00442563","article-title":"Negative symptoms in schizophrenia: a target for new drug development.","volume":"7","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol Ser"},{"key":"R3-12-20210129","first-page":"1263","article-title":"Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.","volume":"29","author":"Yasui-Furukori","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans.","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4.","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","article-title":"Serum concentrations and side effects in psychiatric patients during risperidone therapy.","volume":"20","author":"Olesen","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/clinchem\/46.11.1834","article-title":"CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.","volume":"46","author":"van Schaik","year":"2000","journal-title":"Clin Chem"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/clinchem\/47.6.1104","article-title":"The CYP3A4*33 allele: is it really rare?","volume":"47","author":"van Schaik","year":"2001","journal-title":"Clin Chem"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00228-004-0848-7","article-title":"Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.","volume":"60","author":"Wang","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clpt.2004.08.022","article-title":"Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4 and CYP3A5 genes.","volume":"76","author":"Hesselink","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians.","volume":"48","author":"van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5414\/CPP38069","article-title":"P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.","volume":"38","author":"Fromm","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clpt.2005.03.009","article-title":"Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.","volume":"78","author":"Nakagami","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00008571-200308000-00006","article-title":"Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.","volume":"13","author":"Kroetz","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","article-title":"Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.","volume":"69","author":"Cascorbi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00008571-200103000-00008","article-title":"Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2\/cMOAT, in healthy Japanese subjects.","volume":"11","author":"Ito","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1023\/A:1020433422259","article-title":"Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin.","volume":"19","author":"Horinouchi","year":"2002","journal-title":"Pharmacol Res"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mcp.2002.129196","article-title":"Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.","volume":"72","author":"Johne","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00228-003-0567-5","article-title":"Digoxin pharmacokinetics and MDR1 genetic polymorphisms.","volume":"58","author":"Verstuyft","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V91.5.1749","article-title":"Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors.","volume":"91","author":"Mickley","year":"1998","journal-title":"Blood"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1023\/A:1023282312757","article-title":"MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects.","volume":"20","author":"Morita","year":"2003","journal-title":"Pharmacol Res"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","article-title":"Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","article-title":"Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.pnpbp.2007.04.021","article-title":"Association between major multidrug resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.","volume":"31","author":"Yasui-Furukori","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.","volume":"40","author":"Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2217\/14622416.7.7.987","article-title":"Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.","volume":"7","author":"Xing","year":"2006","journal-title":"Pharmacogenomics"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","article-title":"CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.","volume":"16","author":"Mirghani","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R35-12-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-4347(00)00323-6","article-title":"Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection.","volume":"746","author":"Avenoso","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R36-12-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2710.2007.00811.x","article-title":"Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.","volume":"32","author":"Mahatthanatrakul","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"R37-12-20210129","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.clpt.2005.07.007","article-title":"Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.","volume":"78","author":"Jung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R38-12-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00007691-200306000-00006","article-title":"Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.","volume":"25","author":"Mihara","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R39-12-20210129","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","article-title":"Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.","volume":"36","author":"Vermeir","year":"2008","journal-title":"Drug Met Dispos"},{"key":"R40-12-20210129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":"The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.","volume":"7","author":"Wang","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R41-12-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00008571-200312000-00005","article-title":"Haplotype analysis of ABCB1\/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.","volume":"13","author":"Sai","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R42-12-20210129","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","article-title":"Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.","volume":"21","author":"Melkersson","year":"2006","journal-title":"Hum Psychopharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181858ca9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:55:04Z","timestamp":1738418104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200810000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181858ca9","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}